Literature DB >> 23568100

Overlap between frontotemporal dementia and Alzheimer's disease: cerebrospinal fluid pattern and neuroimaging study.

Alessandro Padovani1, Enrico Premi, Andrea Pilotto, Stefano Gazzina, Maura Cosseddu, Silvana Archetti, Vanessa Cancelli, Barbara Paghera, Barbara Borroni.   

Abstract

BACKGROUND: Differential diagnosis between frontotemporal dementia (FTD) and Alzheimer's disease (AD) is often challenging. Autopsy series have identified AD pathology in a consistent percentage of patients clinically diagnosed with frontotemporal dementia (FTD). It has been demonstrated that the levels of tau and Aβ42 in cerebrospinal fluid (CSF) are a reliable marker for AD.
OBJECTIVE: To evaluate the presence of a CSF AD-like pattern in patients with FTD, and the related brain changes, to assess whether these patients had features resembling an AD pattern of hypoperfusion.
METHODS: Clinically-diagnosed non-monogenic FTD patients underwent an extensive neuropsychological assessment, 99mTc-ECD SPECT, and CSF analysis (tau and Aβ42 levels). FTD AD-like and FTD non-AD-like patterns were identified, and neuropsychological and neuroimaging features compared.
RESULTS: CSF AD-like pattern was reported in 9 cases out of 43 (21%). FTD AD-like and non-AD-like patients did not differ in demographic characteristics, cognitive deficits, or behavioral changes. Both groups had greater hypoperfusion in frontotemporal lobes as compared to age-matched controls. When FTD AD-like patients were compared to the FTD non-AD-like group, the former had greater hypoperfusion in brain areas typically affected by AD, namely precuneus, temporal, and parietal areas.
CONCLUSIONS: CSF AD-like profile in FTD is associated with brain abnormalities typically found in classical AD, confirming the usefulness of CSF testing. Detecting an ongoing AD pathological process in FTD has several implications for defining distinctive treatment approaches, guiding genetic screening, and helping in patient selection in future clinical trials in both FTLD and AD therapeutics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23568100     DOI: 10.3233/JAD-121969

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  6 in total

1.  Amyloid in dementia associated with familial FTLD: not an innocent bystander.

Authors:  Georges Naasan; Gil D Rabinovici; Pia Ghosh; Jonathan D Elofson; Bruce L Miller; Giovanni Coppola; Anna Karydas; Jamie Fong; David Perry; Suzee E Lee; Jennifer S Yokoyama; William W Seeley; Joel H Kramer; Michael W Weiner; Norbert Schuff; William J Jagust; Lea T Grinberg; Mochtar Pribadi; Zhongan Yang; Renee Sears; Eric Klein; Kevin Wojta; Howard J Rosen
Journal:  Neurocase       Date:  2015-06-04       Impact factor: 0.881

Review 2.  Non-Alzheimer's disease-related memory impairment and dementia.

Authors:  Sönke Arlt
Journal:  Dialogues Clin Neurosci       Date:  2013-12       Impact factor: 5.986

Review 3.  Biological, Neuroimaging, and Neurophysiological Markers in Frontotemporal Dementia: Three Faces of the Same Coin.

Authors:  Barbara Borroni; Alberto Benussi; Enrico Premi; Antonella Alberici; Elena Marcello; Fabrizio Gardoni; Monica Di Luca; Alessandro Padovani
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

4.  Evaluating the reliability of neurocognitive biomarkers of neurodegenerative diseases across countries: A machine learning approach.

Authors:  M Belen Bachli; Lucas Sedeño; Jeremi K Ochab; Olivier Piguet; Fiona Kumfor; Pablo Reyes; Teresa Torralva; María Roca; Juan Felipe Cardona; Cecilia Gonzalez Campo; Eduar Herrera; Andrea Slachevsky; Diana Matallana; Facundo Manes; Adolfo M García; Agustín Ibáñez; Dante R Chialvo
Journal:  Neuroimage       Date:  2019-12-10       Impact factor: 6.556

Review 5.  Clinical, biological, and imaging features of monogenic Alzheimer's Disease.

Authors:  Andrea Pilotto; Alessandro Padovani; Barbara Borroni
Journal:  Biomed Res Int       Date:  2013-11-27       Impact factor: 3.411

6.  Increased VLCFA-lipids and ELOVL4 underlie neurodegeneration in frontotemporal dementia.

Authors:  Ying He; Katherine Phan; Surabhi Bhatia; Russell Pickford; YuHong Fu; Yue Yang; John R Hodges; Olivier Piguet; Glenda M Halliday; Woojin Scott Kim
Journal:  Sci Rep       Date:  2021-11-01       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.